Search
Flosatidil
go.drugbank.com/drugs/DB19611ExperimentalThe usage of the INN stem '-dil' in the name indicates that Flosatidil is a vasodilator. Flosatidil has a monoisotopic molecular weight of 525.23 Da.
Pirozadil
go.drugbank.com/drugs/DB19997ExperimentalThe usage of the INN stem '-dil' in the name indicates that Pirozadil is a vasodilator. Pirozadil has a monoisotopic molecular weight of 527.18 Da.
Mefenidil
go.drugbank.com/drugs/DB20187ExperimentalThe usage of the INN stem '-dil' in the name indicates that Mefenidil is a vasodilator. Mefenidil has a monoisotopic molecular weight of 197.1 Da.
Naminidil
go.drugbank.com/drugs/DB20227ExperimentalThe usage of the INN stem '-dil' in the name indicates that Naminidil is a vasodilator. Naminidil has a monoisotopic molecular weight of 269.16 Da.
Semotiadil
go.drugbank.com/drugs/DB20587ExperimentalThe usage of the INN stem '-dil' in the name indicates that Semotiadil is a vasodilator. Semotiadil has a monoisotopic molecular weight of 536.2 Da.
Floredil
go.drugbank.com/drugs/DB20906ExperimentalThe usage of the INN stem '-dil' in the name indicates that Floredil is a vasodilator. Floredil has a monoisotopic molecular weight of 295.18 Da.
Carprazidil
go.drugbank.com/drugs/DB21012ExperimentalThe usage of the INN stem '-dil' in the name indicates that Carprazidil is a vasodilator. Carprazidil has a monoisotopic molecular weight of 291.1 Da.
Biclodil
go.drugbank.com/drugs/DB21180ExperimentalThe usage of the INN stem '-dil' in the name indicates that Biclodil is a vasodilator. Biclodil has a monoisotopic molecular weight of 246.01 Da.
Sinitrodil
go.drugbank.com/drugs/DB21396ExperimentalThe usage of the INN stem '-dil' in the name indicates that Sinitrodil is a vasodilator. Sinitrodil has a monoisotopic molecular weight of 238.06 Da.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigational-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates